Literature DB >> 28983583

Aberrant production of soluble inducible T cell co‑stimulator and soluble programmed cell death protein 1 in patients with chronic hepatitis B.

Dongsheng Wang1, Qin Du1, Guangcheng Luo1, Qiang Wang1, Guangrong Wang1, Guoyuan Zhang1, Zhengwei Leng2, Xiaolan Guo1.   

Abstract

Previous studies demonstrated that immune dysregulation is an important cause of hepatitis B virus (HBV)‑mediated liver damage. Co‑stimulators including programmed cell death protein 1 (PD‑1) and inducible T cell co‑stimulator (ICOS) are involved in the pathogenesis of HBV. In the present study, the serum levels of soluble (s)PD‑1 and sICOS in patients with chronic HBV infections, were investigated, and the association between sPD‑1 and sICOS levels and liver injury degree was investigated. Serum sPD‑1 and sICOS levels were increased in the HBVpatient group particularly in the HBV external core antigen positive group. In the immune clearance group, sPD‑1 and sICOS were increased compared with the tolerance group. Furthermore, the relative mRNA expression levels were also increased in patients with HBV. However there was no correlation between sPD‑1 and sICOS levels and HBV antibodies or PD‑1/ICOS mRNA copies. The altered sPD‑1 and sICOS serum levels in the different HBV groups may reflect the dysregulation of T cell activation, and may be associated with the HBV pathological process.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28983583     DOI: 10.3892/mmr.2017.7630

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  3 in total

Review 1.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

2.  Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued.

Authors:  Guichan Liao; Ziying Liu; Muye Xia; Hongjie Chen; Houji Wu; Bing Li; Tao Yu; Shaohang Cai; Xiaoyong Zhang; Jie Peng
Journal:  Infect Drug Resist       Date:  2022-04-29       Impact factor: 4.177

3.  Orthogonal quantification of soluble inducible T-cell costimulator (ICOS) in healthy and diseased human serum.

Authors:  Kevin McKinski; Dean McNulty; Francesca Zappacosta; Mary Birchler; Matt Szapacs; Christopher Evans
Journal:  J Pharm Anal       Date:  2021-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.